Evidence claim

Relevance of uc-binder-20261022-protocol-adaptyv-bli-affinity to "Which computational design workflow produces binders that work when they are made and tested?"

Evidence concern: excluded from comparisons

The paper prints three different round-1 binder rates and two round-2 expression rates. Section 2.4 gives round 1 as '2.5% (5/201)' and round 2 as 'a 95% expression rate (378 of 400 tested)'; Section 4.1 gives expression as improving 'from 73% to 94%'; Section 4.1 gives the binder percentage as rising 'from 3% in the first round to 13%'. All the printed values are recorded with their locators and none is reconciled here.Crowdsourced Protein Design: Lessons From the Adaptyv EGFR Binder Competition (Cotet et al., bioRxiv 2025) · Sections 2.4, 4.1 and 4.2

Section 4.1 says Figure 8 shows 'the total number of validated binders across the 3 binding thresholds' but no section of the paper defines those three thresholds. No hit definition is therefore recorded for the Figure 8 counts, and the binding protocol's success threshold is left unstated with a reason rather than guessed.Crowdsourced Protein Design: Lessons From the Adaptyv EGFR Binder Competition (Cotet et al., bioRxiv 2025) · Section 4.1; Figure 8 caption

Use case: Design a new binder to a chosen target
Assessed by: Adaptyv EGFR competition BLI affinity
Relevance: Direct evidence
Endpoint: Dissociation constant for EGFR of a competition design, fitted from third-party multi-cycle kinetic BLI

Affinities measured by an independent laboratory on one target, including the only same-assay measurement of a conventionally obtained binder anywhere in this evidence: cetuximab at 9.94 nM on the same instrument as the designs. The best de novo design reached 82 nM and the best optimised antibody 1.21 nM.

3 reviewed evaluations

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

40 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-10-22-1b7cf027e4f6
Property and statement	Original source and location	Review and provenance
Citation locations 2 values locator Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv source id uc-binder-20261022-source-adaptyv-preprint locator Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv source id uc-binder-20261022-source-adaptyv-repo-round2 Context-only references	Crowdsourced Protein Design: Lessons From the Adaptyv EGFR Binder Competition (Cotet et al., bioRxiv 2025) Original source ↗ uc-binder-20261022-source-adaptyv-preprint: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; uc-binder-20261022-source-adaptyv-repo-round2: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: bioRxiv preprint version 1 Retrieved: 2026-10-22T12:01:00Z	not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit details Field: `attributes.citation_locators` Source artifact SHA-256: `17039d69ecc37f45f6c402511b8f4497ce631003689fa95ad1ab221f8f787a4f` Hash scope: SHA-256 of one retrieval of a mutable web page. The hash describes that retrieval, not a stable artifact. Inspected artifact
Citation locations 2 values locator Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv source id uc-binder-20261022-source-adaptyv-preprint locator Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv source id uc-binder-20261022-source-adaptyv-repo-round2 Context-only references	Adaptyv EGFR design competition round 2 results repository Original source ↗ uc-binder-20261022-source-adaptyv-preprint: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; uc-binder-20261022-source-adaptyv-repo-round2: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: commit fc91b91ddc367830b755b215dbc69669675ad6a0 Retrieved: 2026-10-22T12:02:00Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.citation_locators` Source artifact SHA-256: `b98dd231fa663e10e2768ad0cb7c8b33ba993bc809bd6168390ac87120ce3b7b` Hash scope: Hash scope not separately documented; inspect source record Archive member: results/result_summary.csv at commit fc91b91ddc367830b755b215dbc69669675ad6a0 Inspected artifact
Comparison group binder-affinities Context-only references	Crowdsourced Protein Design: Lessons From the Adaptyv EGFR Binder Competition (Cotet et al., bioRxiv 2025) Original source ↗ uc-binder-20261022-source-adaptyv-preprint: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; uc-binder-20261022-source-adaptyv-repo-round2: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: bioRxiv preprint version 1 Retrieved: 2026-10-22T12:01:00Z	not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit details Field: `attributes.comparison_group` Source artifact SHA-256: `17039d69ecc37f45f6c402511b8f4497ce631003689fa95ad1ab221f8f787a4f` Hash scope: SHA-256 of one retrieval of a mutable web page. The hash describes that retrieval, not a stable artifact. Inspected artifact
Comparison group binder-affinities Context-only references	Adaptyv EGFR design competition round 2 results repository Original source ↗ uc-binder-20261022-source-adaptyv-preprint: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; uc-binder-20261022-source-adaptyv-repo-round2: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: commit fc91b91ddc367830b755b215dbc69669675ad6a0 Retrieved: 2026-10-22T12:02:00Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.comparison_group` Source artifact SHA-256: `b98dd231fa663e10e2768ad0cb7c8b33ba993bc809bd6168390ac87120ce3b7b` Hash scope: Hash scope not separately documented; inspect source record Archive member: results/result_summary.csv at commit fc91b91ddc367830b755b215dbc69669675ad6a0 Inspected artifact
Comparison title Affinity of the best binder found per target Context-only references	Crowdsourced Protein Design: Lessons From the Adaptyv EGFR Binder Competition (Cotet et al., bioRxiv 2025) Original source ↗ uc-binder-20261022-source-adaptyv-preprint: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; uc-binder-20261022-source-adaptyv-repo-round2: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: bioRxiv preprint version 1 Retrieved: 2026-10-22T12:01:00Z	not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit details Field: `attributes.comparison_title` Source artifact SHA-256: `17039d69ecc37f45f6c402511b8f4497ce631003689fa95ad1ab221f8f787a4f` Hash scope: SHA-256 of one retrieval of a mutable web page. The hash describes that retrieval, not a stable artifact. Inspected artifact
Comparison title Affinity of the best binder found per target Context-only references	Adaptyv EGFR design competition round 2 results repository Original source ↗ uc-binder-20261022-source-adaptyv-preprint: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; uc-binder-20261022-source-adaptyv-repo-round2: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: commit fc91b91ddc367830b755b215dbc69669675ad6a0 Retrieved: 2026-10-22T12:02:00Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.comparison_title` Source artifact SHA-256: `b98dd231fa663e10e2768ad0cb7c8b33ba993bc809bd6168390ac87120ce3b7b` Hash scope: Hash scope not separately documented; inspect source record Archive member: results/result_summary.csv at commit fc91b91ddc367830b755b215dbc69669675ad6a0 Inspected artifact
Constraints 3 values The 1.21 nM winner is an optimisation of cetuximab, not a de novo design, so it is not comparable with de novo affinities. Cetuximab's 9.94 nM is a positive control for assay validity. It says what a conventional binder achieves on this target; it says nothing about the hit rate of conventional methods, because no library campaign was run. Only the affinities printed in the prose are recorded. The distribution over all 60 binders is in Figure 10, which was not read. Context-only references	Crowdsourced Protein Design: Lessons From the Adaptyv EGFR Binder Competition (Cotet et al., bioRxiv 2025) Original source ↗ uc-binder-20261022-source-adaptyv-preprint: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; uc-binder-20261022-source-adaptyv-repo-round2: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: bioRxiv preprint version 1 Retrieved: 2026-10-22T12:01:00Z	not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit details Field: `attributes.constraints` Source artifact SHA-256: `17039d69ecc37f45f6c402511b8f4497ce631003689fa95ad1ab221f8f787a4f` Hash scope: SHA-256 of one retrieval of a mutable web page. The hash describes that retrieval, not a stable artifact. Inspected artifact
Constraints 3 values The 1.21 nM winner is an optimisation of cetuximab, not a de novo design, so it is not comparable with de novo affinities. Cetuximab's 9.94 nM is a positive control for assay validity. It says what a conventional binder achieves on this target; it says nothing about the hit rate of conventional methods, because no library campaign was run. Only the affinities printed in the prose are recorded. The distribution over all 60 binders is in Figure 10, which was not read. Context-only references	Adaptyv EGFR design competition round 2 results repository Original source ↗ uc-binder-20261022-source-adaptyv-preprint: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; uc-binder-20261022-source-adaptyv-repo-round2: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: commit fc91b91ddc367830b755b215dbc69669675ad6a0 Retrieved: 2026-10-22T12:02:00Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.constraints` Source artifact SHA-256: `b98dd231fa663e10e2768ad0cb7c8b33ba993bc809bd6168390ac87120ce3b7b` Hash scope: Hash scope not separately documented; inspect source record Archive member: results/result_summary.csv at commit fc91b91ddc367830b755b215dbc69669675ad6a0 Inspected artifact
Endpoint Dissociation constant for EGFR of a competition design, fitted from third-party multi-cycle kinetic BLI Context-only references	Crowdsourced Protein Design: Lessons From the Adaptyv EGFR Binder Competition (Cotet et al., bioRxiv 2025) Original source ↗ uc-binder-20261022-source-adaptyv-preprint: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; uc-binder-20261022-source-adaptyv-repo-round2: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: bioRxiv preprint version 1 Retrieved: 2026-10-22T12:01:00Z	not individually reviewed No individual claim review recorded Source has a recorded evidence concern. Consult its source page before using the claim. Audit details Field: `attributes.endpoint` Source artifact SHA-256: `17039d69ecc37f45f6c402511b8f4497ce631003689fa95ad1ab221f8f787a4f` Hash scope: SHA-256 of one retrieval of a mutable web page. The hash describes that retrieval, not a stable artifact. Inspected artifact
Endpoint Dissociation constant for EGFR of a competition design, fitted from third-party multi-cycle kinetic BLI Context-only references	Adaptyv EGFR design competition round 2 results repository Original source ↗ uc-binder-20261022-source-adaptyv-preprint: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; uc-binder-20261022-source-adaptyv-repo-round2: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv Shared locator for this statement’s cited sources; not a separate locator for each citation. Version: commit fc91b91ddc367830b755b215dbc69669675ad6a0 Retrieved: 2026-10-22T12:02:00Z	not individually reviewed No individual claim review recorded Audit details Field: `attributes.endpoint` Source artifact SHA-256: `b98dd231fa663e10e2768ad0cb7c8b33ba993bc809bd6168390ac87120ce3b7b` Hash scope: Hash scope not separately documented; inspect source record Archive member: results/result_summary.csv at commit fc91b91ddc367830b755b215dbc69669675ad6a0 Inspected artifact

How to read the evidence

Sources and history

Release 2026-10-22-1b7cf027e4f6 · Record review: source checked

2 source records and release history

Crowdsourced Protein Design: Lessons From the Adaptyv EGFR Binder Competition (Cotet et al., bioRxiv 2025) · Original source · bioRxiv preprint version 1
Adaptyv EGFR design competition round 2 results repository · Original source · commit fc91b91ddc367830b755b215dbc69669675ad6a0

Download this release (gzip)

Technical metadata and extraction receipts

Stable ID: use-case-mapping-binder-20261022-adaptyv-bli-affinity

citation locators: locator: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; source id: uc-binder-20261022-source-adaptyv-preprint; locator: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; source id: uc-binder-20261022-source-adaptyv-repo-round2
comparison group: binder-affinities
comparison title: Affinity of the best binder found per target
constraints: The 1.21 nM winner is an optimisation of cetuximab, not a de novo design, so it is not comparable with de novo affinities.; Cetuximab's 9.94 nM is a positive control for assay validity. It says what a conventional binder achieves on this target; it says nothing about the hit rate of conventional methods, because no library campaign was run.; Only the affinities printed in the prose are recorded. The distribution over all 60 binders is in Figure 10, which was not read.
endpoint: Dissociation constant for EGFR of a competition design, fitted from third-party multi-cycle kinetic BLI
field: links:assessed_by:uc-binder-20261022-protocol-adaptyv-bli-affinity
headline metric: dissociation-constant
limitations: Preprint, not peer reviewed, written by the organisers.; Only a handful of the 60 measured affinities are printed in the prose.; Section 4.3 reports no statistically significant difference in median affinity between the two rounds.; No uncertainty is printed in the prose for individual values.
rationale: Affinities measured by an independent laboratory on one target, including the only same-assay measurement of a conventionally obtained binder anywhere in this evidence: cetuximab at 9.94 nM on the same instrument as the designs. The best de novo design reached 82 nM and the best optimised antibody 1.21 nM.
reason: Add measured de novo binder design outcomes from the 2026-10-22 use-case evidence pass (#176).
relevance: direct
review: artifact sha256: 17039d69ecc37f45f6c402511b8f4497ce631003689fa95ad1ab221f8f787a4f; method: scope-review; independent-cell-check; ai-assisted-source-review; method note: Re-downloaded (HTTP 200, 493,217 bytes, the same byte count as the pinned retrieval) but the SHA-256 differs, as expected for a mutable bioRxiv page whose hash describes one retrieval. Every extracted value and every quoted sentence was then located verbatim in the new retrieval, so the difference is in page furniture and not in the evidence. One section attribution and one quotation were corrected.; note: Reviewed in docs/reviews/use-cases/binder-2026-10-22.md. Automated AI review of the source transcription only; it is not human scientific review and nothing here was reproduced experimentally.; retrieval url: https://www.biorxiv.org/content/10.1101/2025.04.17.648362v1.full; reviewed at: 2026-10-22T15:00:00Z; reviewer: claude; reviewer note: Claude review agent, independent of the extraction agent; no human review claimed; scope: Endpoint fit, relevance grade, constraints, limitations, comparison grouping and the evaluations listed in reviewed_evaluations.
reviewed evaluations: uc-binder-20261022-eval-adaptyv-bindcraft-r1-affinity; uc-binder-20261022-eval-adaptyv-bindcraft-r2-affinity; uc-binder-20261022-eval-adaptyv-cradle-r2-affinity
revision: 1
source locator: uc-binder-20261022-source-adaptyv-preprint: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv; uc-binder-20261022-source-adaptyv-repo-round2: Section 2.3; Sections 3.1, 3.2 and 4.3; results/result_summary.csv
stratum label: Adaptyv EGFR competition, third-party BLI
stratum order: 3
value: uc-binder-20261022-protocol-adaptyv-bli-affinity
pins: record id: uc-binder-20261022-eval-adaptyv-bindcraft-r1-affinity; fields: status; links; attributes.origin; attributes.comparison; sha256: 706b131e5c29c06a5ccbfc95c26cd914e379a22977b187a4593e329036272a7a; record id: uc-binder-20261022-eval-adaptyv-bindcraft-r2-affinity; fields: status; links; attributes.origin; attributes.comparison; sha256: 9bbc1872f3b8140de381069e6a718b2fd84ec2a38e188152c39ef66b6dce006a; record id: uc-binder-20261022-eval-adaptyv-cradle-r2-affinity; fields: status; links; attributes.origin; attributes.comparison; sha256: e9b7e4cbb4f99137e91705c49b354107da8abcd1e035a03daae17e5de1966b7e; record id: uc-binder-20261022-protocol-adaptyv-bli-affinity; fields: status; name; description; facets; source_ids; links; attributes; sha256: 4b038b7ea3ddcdb4a2340926425fa4d02a2cd72899a69fdf9033196c0103d654; record id: uc-binder-20261022-result-adaptyv-bindcraft-r1-kd; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 69fd261f63098bbc82842ff971900cc91a04084d1f57df7370fc3968c4424eae; record id: uc-binder-20261022-result-adaptyv-bindcraft-r2-kd; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: fc7908176be5146fce3d66483b8c3fcd80e657a197ea2bf5c8d20980aa5b4996; record id: uc-binder-20261022-result-adaptyv-cradle-r2-kd; fields: status; attributes.metric; attributes.metric_qualifier; attributes.printed_value; attributes.numeric_value; sha256: 19c99bbaea85213cbb4801895cea6a365b7eca10823a829ae5c6987381637cf1; record id: uc-binder-20261022-source-adaptyv-preprint; fields: status; attributes.artifact_sha256; sha256: 379c0dd17d6ebf91ee5b1d65f3247c89c6c16509fc4c6a764416712b02ec8f2d; record id: uc-binder-20261022-source-adaptyv-repo-round2; fields: status; attributes.artifact_sha256; sha256: e3c1d86215efce7858743e0d5c57ce1443e3d19707a096e2e1c87c1dcc1d138b; record id: use-case-de-novo-binder-design; fields: status; name; description; facets; attributes.question; attributes.decision; attributes.inputs; attributes.output; attributes.exclusions; attributes.setting; attributes.clinical_scope; attributes.intended_users; sha256: b5a0012d1b0f02d6bd7466b7308123b26e676eda8ef54d706c865bb3f777e5b9

Related records

subject: Design a new binder to a chosen target

Suggest a correction